The HHS National Alzheimer's Plan, the federal roadmap for dementia research and care, prioritizes risk reduction, innovation, care, and family support through 2035. For rural families, Medicare drug coverage stays narrow, coinsurance can exceed $5,000 per year, and PET and infusion travel can take hours.
About 7.2 million Americans age 65 and older had Alzheimer's in 2025, reports the Alzheimer's Association. Paid care reached $384 billion, while about 12 million caregivers gave 19.2 billion unpaid hours. This article explains what changed, what Medicare covers, what it costs, and how rural families can plan.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What changed in the 2026 update?
- What does Medicare cover now?
- How much could treatment cost?
- Why is rural access harder?
- What can rural families do next?
What changed in the 2026 update?
Congress extended the National Alzheimer's Project through 2035 in the NAPA Reauthorization Act, enacted October 1, 2024, according to Congress.gov. HHS announced the 2026 Update on October 22, 2026, as reported by South Florida Hospital News, replacing six older goals with four, detailed in the HHS announcement.
The four areas are risk reduction, innovation, care, and family supports. For families, the shift matters because care coordination and caregiver support sit alongside drug development as stated aims. It does not by itself expand who qualifies for treatment or pay for travel.
What does Medicare cover now?
CMS launched the 8-year GUIDE dementia-care model on July 1, 2024, according to the CMS Innovation Center blog. It works with 390 organizations building Dementia Care Programs that serve hundreds of thousands of people on Medicare. Availability varies by place, so families must ask whether a local program takes part.
CMS says Medicare covers Leqembi only for a narrow early-stage group, described in the CMS coverage statement. The limits exclude moderate or advanced dementia and cases without confirmed amyloid. Families should confirm stage, test results, and registry status before planning infusions.
- mild cognitive impairment or mild dementia
- documented amyloid plaque
- clinician in a qualifying registry
How much could treatment cost?
MedCompanions reporting lists Leqembi at about $26,500 per year and Kisunla at about $32,000 per 12 months, shown in the price comparison. The same reporting notes standard 20% Part B coinsurance can exceed $5,000 yearly before scans and infusions.
FDA gave traditional approval to Leqembi in July 2023 and to Kisunla in July 2024, according to UCLA Easton Center and FDA timeline reporting. Both drugs are only for early symptomatic disease with confirmed amyloid. That narrow window makes early testing and specialist review central to cost planning.
Why is rural access harder?
In Georgia's 159 counties, no rural county had a PET facility, University of Georgia researchers found in the university release. They found only one rural county had an infusion center.
In that study, rural drives exceeded one hour for PET and three hours for infusions. Distance affects amyloid confirmation, treatment start, and caregiver time off work. A family weighing therapy must add fuel, lodging, and missed work to drug coinsurance.
What can rural families do next?
Start with eligibility and location checks before budgeting for travel. Bring cognitive test history, medication list, and insurance card to the visit.
Ask the clinic whether it joins a GUIDE Dementia Care Program and where it refers for PET and infusions. Ask about caregiver respite, care navigation, and follow-up schedules if travel is long. Write down drive times and total fees before agreeing to start.
